Developing Lung Cancer Screening in Hodgkin Lymphoma Survivors: a Qualitative Study

September 2, 2020 updated by: The Christie NHS Foundation Trust
To explore the topic of lung cancer screening following treatment for Hodgkin lymphoma from the perspective of survivors

Study Overview

Status

Completed

Conditions

Detailed Description

Explore survivors' attitudes towards lung cancer and lung cancer screening Explore survivors' understanding of cancer screening as a concept and the benefits of screening and early detection Explore survivors' level of awareness of and attitudes towards their lung cancer risk Explore survivors' views on the barriers and motivating factors that would impact their decision to attend a lung cancer screening test

Study Type

Observational

Enrollment (Actual)

30

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United Kingdom
      • Manchester, United Kingdom, M20 4BX
        • Christie NHS Foundation Trust

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Participants who have previously been treated for Hodgkin lymphoma without evidence of relapse for at least 5 years

Description

Inclusion Criteria:

  • Details held in the ADAPT database at The Christie NHS Foundation trust
  • Responded to most recent ADAPT study questionnaire (April - August 2019)
  • Aged 18-80
  • Previously treated for Hodgkin lymphoma without evidence of relapse for at least 5 years
  • Able to provide informed consent
  • Treated with radiotherapy (with lung tissue in the radiotherapy field) and/or alkylating agent containing chemotherapy.

Exclusion Criteria:

  • Previous or current diagnosis of lung cancer
  • Stated within 2019 health questionnaire that they did not wish to be contacted
  • Have participated in lung cancer screening through the Manchester Lung Health Checks

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Explore survivors' attitudes towards lung cancer and lung cancer screening
Time Frame: 6 months
Semi-structured interviews
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

The Christie NHS Foundation Trust

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 11, 2020

Primary Completion (Actual)

April 13, 2020

Study Completion (Actual)

April 13, 2020

Study Registration Dates

First Submitted

January 31, 2020

First Submitted That Met QC Criteria

May 15, 2020

First Posted (Actual)

May 20, 2020

Study Record Updates

Last Update Posted (Actual)

September 3, 2020

Last Update Submitted That Met QC Criteria

September 2, 2020

Last Verified

September 1, 2020

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CFTSp178
  • 276443 (Other Identifier: IRAS Project ID)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

It is not intended to share IPD with other researchers outside the study team

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe